Dynavax Technologies Stock Fair Value Calculator – Short Interest in Dynavax Technologies Co. Plummets

☀️Trending News

Short Interest in Dynavax Technologies ($NASDAQ:DVAX) Co. has seen a significant decrease recently. This is great news for the company, as it indicates a high level of confidence among investors and traders. Dynavax Technologies Co. is a biopharmaceutical company that specializes in developing and commercializing vaccines and therapeutics. In addition to the vaccine, Dynavax Technologies Co. also develops and commercializes immuno-oncology products and other therapeutics. These products are designed to promote the body’s natural immune response to diseases and illnesses, such as cancer, colorectal cancer, and more.

The company also has a number of collaborations and strategic partnerships with various pharmaceutical companies. The decrease in short interest is likely due to the company’s strong financial performance and positive outlook for the future. This is further bolstered by the success of their vaccines and other products. As such, the decrease in short interest reflects investor confidence in Dynavax Technologies Co.’s ability to continue producing successful products and consistent financial performance.

Price History

The stock opened at $14.3 and closed at $14.5, up 1.6% from the previous closing price of $14.2. This is a significant decrease from the month before, as the short interest on DVAX had been steadily increasing since October of last year. This is good news for shareholders, as it may signal that investors are becoming more optimistic about the company’s prospects. The drop in short interest suggests that investors who had been bearish on the stock are now beginning to take a more positive view of the company.

It may also be an indication that investors are beginning to recognize the long-term potential of Dynavax’s pipeline of products and services. Overall, this decrease in short interest could indicate a shift in sentiment among investors and could be a harbinger of a bright future for Dynavax Technologies Co. Investors should continue to monitor the stock closely to see if the current trend continues or if the short interest begins to rise again. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Dynavax Technologies. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Dynavax Technologies. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Dynavax Technologies. More…

Key Ratios Snapshot

Some of the financial key ratios for Dynavax Technologies are shown below. More…

Analysis – Dynavax Technologies Stock Fair Value Calculator

At GoodWhale, we have taken a deep dive into DYNAVAX TECHNOLOGIES‘s financials in order to provide you with an accurate valuation of the company’s stock. Through our proprietary Valuation Line, we estimate the intrinsic value of DYNAVAX TECHNOLOGIES share to be around $14.6. Currently, DYNAVAX TECHNOLOGIES stock is being traded at $14.5, which suggests that it is fairly priced given our estimated intrinsic value. More…

Peers

The market for Dynavax Technologies Corp is quite competitive. The company’s main competitors are Foresee Pharmaceuticals Co Ltd, Aeolus Pharmaceuticals Inc, and Kala Pharmaceuticals Inc. All of these companies are vying for a share of the market, and each has its own strengths and weaknesses. Dynavax Technologies Corp must keep an eye on all of its competitors in order to stay ahead in the market.

– Foresee Pharmaceuticals Co Ltd ($TPEX:6576)

Foresee Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 8.77B as of 2022. The company has a Return on Equity of -22.28%. The company focuses on the development and commercialization of innovative drugs for the treatment of cancer and other diseases. The company’s products include F-76, a phase III clinical candidate for the treatment of ovarian cancer; and F-288, a phase II clinical candidate for the treatment of solid tumors. Foresee Pharmaceuticals Co Ltd was founded in 2007 and is headquartered in Taipei, Taiwan.

– Aeolus Pharmaceuticals Inc ($OTCPK:AOLS)

Aeolus Pharmaceuticals Inc is a pharmaceutical company that focuses on the development of treatments for a variety of conditions. The company’s market cap is $167.29k and its ROE is -383.62%. Aeolus Pharmaceuticals Inc’s main product is a treatment for a condition called idiopathic pulmonary fibrosis. The company is also developing treatments for other conditions, including cancer and Alzheimer’s disease.

– Kala Pharmaceuticals Inc ($NASDAQ:KALA)

Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of eye diseases. The company’s lead product candidate, KPI-121, is a topical ocular formulation of loteprednol etabonate in development for the treatment of pain and inflammation associated with ocular surgery. Kala Pharmaceuticals Inc has a market cap of 7.69M as of 2022, a Return on Equity of 435.55%. The company’s focus on the development and commercialization of therapies for the treatment of eye diseases makes it a promising investment for those interested in the healthcare sector.

Summary

Dynavax Technologies Corporation is a biopharmaceutical company that specializes in the development of novel products to prevent and treat infectious and inflammatory diseases. Recently, an analysis of short interest data revealed a significant decrease in the number of shorted shares held by investors. This could indicate a shift in sentiment from bearish to bullish, as investors begin to take a more positive outlook on the company’s future prospects. This decrease may be viewed as an opportunity for investors to consider investing in Dynavax Technologies, as the stock may be undervalued given its potential long-term growth.

However, it is important to note that the current market should be monitored and analyzed closely before making any investment decisions.